Get the Stockscreener App
12.93
1.36%
0.37
Benitec Biopharma Inc stock is traded at $12.93, with a volume of 40,498.
It is up +1.36% in the last 24 hours and down -0.38% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$12.56
Open:
$12.52
24h Volume:
40,498
Relative Volume:
0.33
Market Cap:
$443.51M
Revenue:
$7,000
Net Income/Loss:
$-41.54M
P/E Ratio:
-13.92
EPS:
-0.929
Net Cash Flow:
$-20.57M
1W Performance:
-7.61%
1M Performance:
-0.38%
6M Performance:
+22.95%
1Y Performance:
-2.14%
1-Day Range:
$11.88
$12.98
1-Week Range:
$11.88
$13.96
52-Week Range:
$9.85
$16.76
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
12.91 | 431.49M | 7,000 | -41.54M | -20.57M | -0.929 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.90 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.82 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.68 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.27 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Trading Systems Reacting to (BNTC) Volatility - Stock Traders Daily
Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above 50 Day Moving AverageTime to Sell? - marketbeat.com
Benitec Biopharma Inc (BNTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth - Moomoo
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Sahm
How Benitec Biopharma Inc. (BNTC) Affects Rotational Strategy Timing - Stock Traders Daily
Benitec Biopharma (BNTC) Slips 1.26% as Shares Test Key Support at $11.12Factor Crowding - dars.gov.et
Benitec Biopharma (NASDAQ:BNTC) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Benitec Biopharma Inc (BNTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BNTC Initiated by Wedbush -- Rating Set to Outperform with PT at $16.00 - GuruFocus
Wedbush Initiates Coverage on Benitec Biopharma (BNTC) with Outp - GuruFocus
Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Benitec Biopharma Inc (BNTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Benitec Biopharma Inc (BNTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.710|Chg%:+0.240 - TradingKey
Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.540|Chg%:+0.070 - TradingKey
TradingKey - TradingKey
Benitec Biopharma Inc (BNTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.470|Chg%:+0.030 - TradingKey
Benitec Biopharma Inc (BNTC) Institutional Confidence - TradingKey
(BNTC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Benitec Biopharma (BNTC) Retraces 1.72% – Navigating Key Support and Resistance LevelsFibonacci Time Zone - dars.gov.et
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
BNTC Q2 2026 Earnings: Narrowed Loss Beats Expectations Amid Pipeline ProgressEarnings Trend Analysis - dars.gov.et
BNTC Q2 2026 Earnings: Narrower Loss Exceeds Expectations; Stock Slightly LowerEarnings Trend Analysis - dars.gov.et
Price to sales forward of Benitec Biopharma Inc. – NASDAQ:BNTC - TradingView
BNTCBenitec Biopharma Inc Latest SEC Filings - Finviz
BNTC Stock Price, Quote & Chart - ChartMill
Form 4 Benitec Biopharma Ltd ADR For: 30 June By Investing.com - Investing.com Nigeria
Responsive Playbooks and the BNTC Inflection - Stock Traders Daily
Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund - Stock Titan
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2000 Value Benchmark - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000E Value Benchmark - marketscreener.com
Benitec Biopharma Inc Actuals & Estimates (NASDAQ:BNTC) - TradingView
BNTC Forecast — Price Target — Prediction for 2027 - TradingView
Benitec Biopharma Inc (BNTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
BNTC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentEarnings Weakness Phase - po-news-eg.net
Understanding the Setup: (BNTC) and Scalable Risk - Stock Traders Daily
Benitec Biopharma Inc (BNTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty - GuruFocus
Guggenheim Downgrades Benitec Biopharma(BNTC.US) to Hold Rating - Moomoo
The Technical Signals Behind (BNTC) That Institutions Follow - Stock Traders Daily
BNTC Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Clinical ProgressInterim Report - newsline.com
Benitec Biopharma (BNTC) Slides 2.22% as Shares Approach Critical SupportSentiment Shift - dars.gov.et
Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term OutlookGamma Flip Level - The Legal Advocate
Benitec Biopharma Announces Board Changes and New Director - The Globe and Mail
Benitec BiopharmaCFO Megan Boston Resigns From Board Effective May 22, 2026 - TradingView
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):